Instrumento Inactivo

Otros idiomas CEL-SCI Corporation Nyse

Acciones

US1508374097

Precio de cierre Nyse Otros sitios de cotización
- ^USD	-

15/05	CEL-SCI Corporation informa de los resultados del segundo trimestre y de los seis meses finalizados el 31 de marzo de 2024	CI
08/05	Cel-Sci obtiene el visto bueno de la FDA de EE.UU. para proceder con el estudio de confirmación del fármaco contra el cáncer Multikine	MT

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Cel-Sci: Fiscal Q2 Earnings Snapshot	16/05
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results	16/05
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	15/05
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head and Neck Cancer	09/05
Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine	08/05
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	08/05
CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine	08/05
CEL-SCI Corporation Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	08/05
CEL-SCI Appoints Mario Gobbo to Its Board of Directors	23/04
CEL-SCI Corporation Appoints Mario Gobbo as Board of Directors	23/04
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology	19/03
CEL-SCI Corporation Issues Letter to Shareholders	06/03
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results	15/02
Cel-Sci: Fiscal Q1 Earnings Snapshot	14/02
CEL-SCI Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	14/02
CEL-SCI Corporation (von First Berlin Equity Research GmbH...	14/02
Cel-Sci Closes $7.8 Million Share Offering	13/02
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock	13/02
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock	12/02
Health Care Slips on Rotation to High-Risk Sectors -- Health Care Roundup	10/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas CEL-SCI Corporation Nyse

Acciones

US1508374097

Otros idiomas

Filtros